查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2000722

疫苗輸送裝置市場：依裝置類型、給藥途徑、產品形式及最終用戶分類－2026-2032年全球市場預測

Vaccine Delivery Devices Market by Device Type, Administration Route, Product Form, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，疫苗輸送設備市場價值將達到 84.3 億美元，到 2026 年將成長至 93.2 億美元，到 2032 年將達到 172.5 億美元，年複合成長率為 10.77%。

主要市場統計數據
基準年 2025 84.3億美元
預計年份：2026年 93.2億美元
預測年份 2032 172.5億美元
複合年成長率 (%) 10.77%

對多方面的疫苗輸送設備市場進行策略性展望，重點在於臨床需求、技術進步、供應鏈複雜性和數位化整合。

疫苗輸送裝置產業處於臨床需求、技術創新和複雜法律規範的交匯點。近年來，我們見證了疫苗傳輸裝置從純粹的機械式一次性產品轉變為整合系統，後者融合了人體工學、互聯性、低溫運輸相容性和用戶安全性等要素。這項轉變受到雙重壓力的驅動：一是免疫接種計畫的擴展，二是治療性生物製藥日益複雜，需要精準給藥、確保低溫運輸完整性並監測用藥依從性。

數位連接、人性化的安全、模組化製造、監管清晰和供應鏈韌性的融合正在改變疫苗輸送設備的格局。

多項變革正在重塑疫苗輸送裝置的設計、製造、監管和部署方式。首先，數位化整合和連網型設備的成熟正在改變人們對接種後監測、用藥依從性分析和遠端臨床監測的預期。這一趨勢不僅限於基本的連接，還包括安全的數據處理、設備認證以及分析輸出，這些輸出都能為個別患者照護和人群免疫策略提供資訊。

評估 2025 年實施的關稅措施如何重塑整個生態系統的供應鏈採購決策、採購架構和設備開發重點。

2025年實施的關稅措施影響了美國的進出口貿易，對製造商、供應商和醫療保健機構產生了一系列累積影響。這些關稅措施提高了許多醫療設備類別中使用的進口零件的相對成本，立即給籌資策略帶來壓力，並促使人們重新評估全球供應商基礎。對於依賴海外精密模塑塑膠零件、電子感測器或滅菌服務的醫療設備而言，關稅負擔正在加速關於本地生產和雙重採購安排的討論。

從醫療設備類型、給藥途徑、最終用戶環境和製劑形式等方面進行詳細的觀點，為策略性定位提供指南。

深入了解市場區隔對於使產品策略與臨床和商業性實際情況相符至關重要。從醫療設備類型來看，市場包括自動注射器、輸液幫浦、噴射注射器、筆式注射器、預填充式注射器和安全注射器。自動注射器包括一次性使用裝置和可重複使用平台，後者又可細分為電子式和機械式，兩者對生命週期成本、訓練負擔和資料收集的影響各不相同。輸液幫浦涵蓋彈性體、注射器和容積式三種類型，其中容積式輸液幫浦可細分為攜帶式和固定式系統，以適應不同的護理環境和劑量需求。

美洲、歐洲、中東和非洲以及亞太地區的區域差異和採用趨勢會影響設備選擇、製造和採購。

區域趨勢持續以不同的方式影響技術應用、監管合規和供應商關係。在美洲，採購模式和大規模免疫接種計畫正在推動對兼顧單位效率和安全性的設備的需求。此外，能夠與免疫接種登記系統和電子健康記錄整合的連網型設備也越來越受到關注。該地區關於近岸外包和擴大生產規模以應對全球供應鏈中斷的討論也在不斷升溫。

企業平台策略、策略聯盟、監管因應措施和服務模式如何重新定義醫療設備製造商的競爭優勢。

主要企業的競爭與合作正以多種可預見的方式塑造疫苗輸送裝置的演變。領先的製造商正投資於平台策略，使其能夠在多個治療領域擴展裝置功能，同時分攤研發和監管成本。裝置公司與生技藥品研發公司之間的合作日益普遍，這反映出在研發早期階段檢驗裝置與藥物的兼容性以及設計整合式患者支援方案的必要性。

為醫療設備製造商和醫療保健提供者提供切實可行的策略措施，以增強韌性、加快部署，並在所有醫療保健環境中提供永續價值。

產業領導企業應採取多管齊下的策略，兼顧短期韌性和長期創新。首先，應實現供應商組合多元化，投資關鍵零件的雙重採購，並評估近岸外包機會，以降低關稅波動和物流中斷帶來的風險。其次，應優先發展模組化產品平台，實現一次性組件和可重複使用組件之間的快速重構，並在設計時充分考慮與數位醫療生態系統的互通性，從而提升臨床價值。

為了檢驗我們的見解，我們採用了一種綜合性的混合研究途徑，結合了初步訪談、監管和專利審查、供應鏈映射和情境分析。

本研究整合了多種資料流，以得出可靠且基於證據的結論。初步調查包括對醫療設備工程師、醫院和門診臨床負責人、採購負責人以及監管專家進行結構化訪談，以收集有關器械性能、易用性和供應限制的第一手資訊。專家研討會和諮詢委員會則提供了關於臨床工作流程解讀以及臨床醫生在選擇不同給藥途徑或產品形式的器械時面臨的實際權衡的見解。

整合策略挑戰，展示技術、法規、市場區隔和供應彈性應如何整合，以提供有效的疫苗交付解決方案。

疫苗輸送裝置的格局正經歷著一場精心策劃的變革，其驅動力來自不斷發展的技術能力、監管環境的變化以及人們對安全性和供應穩定性的日益成長的期望。裝置創新不僅因其產品本身的特性而備受重視，更因其能夠顯著改善臨床工作流程、提高依從率和增強系統整體可靠性而受到關注。供應鏈和貿易趨勢正在加速策略轉型，包括供應商多元化、模組化生產方式以及重新聚焦於能夠帶來營運優勢的區域生產能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：疫苗輸送裝置市場：依裝置類型分類

  • 自動注射器
    • 一次性自動注射器
    • 可重複使用的電子自動注射器
    • 機械式可重複使用汽車噴油器
  • 點滴幫浦
    • 彈性體泵
    • 注射式幫浦
    • 容積式泵
      • 攜帶式容積泵
      • 固定式容積泵
  • 噴射注射器
  • 無針注射器
    • 液體注射器
    • 粉末注射器
  • 筆式注射器
    • 一次性筆式注射器
    • 可重複使用的筆式注射器
      • 電子可重複使用筆式注射器
      • 機械式可重複使用筆型注射器
  • 預填充式注射器

第9章：依給藥途徑分類的疫苗給藥裝置市場

  • 皮內注射
  • 肌肉內注射
  • 靜脈注射
  • 黏膜給藥
    • 鼻腔給藥
    • 口服
  • 皮下注射

第10章：疫苗輸送裝置市場：依產品類型分類

  • 液體
  • 冷凍乾燥製劑

第11章：疫苗輸送裝置市場：依最終用戶分類

  • 門診部
  • 診所
    • 基層醫療診所
    • 專科診所
  • 居家醫療
  • 醫院

第12章：疫苗輸送裝置市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：疫苗輸送裝置市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：疫苗輸送裝置市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國疫苗輸送裝置市場

第16章：中國疫苗注射器材市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • AptarGroup, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Catalent, Inc.
  • Consort Medical plc
  • Elcam Medical
  • Gerresheimer AG
  • Inovio Pharmaceuticals, Inc.
  • Nipro Corporation
  • PharmaJet, Inc.
  • SCHOTT AG
  • Stevanato Group SpA
  • Terumo Corporation
  • Vaxxas Pty Ltd
  • Vetter Pharma International GmbH
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG
Product Code: MRR-02026C4C8C99

The Vaccine Delivery Devices Market was valued at USD 8.43 billion in 2025 and is projected to grow to USD 9.32 billion in 2026, with a CAGR of 10.77%, reaching USD 17.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.43 billion
Estimated Year [2026] USD 9.32 billion
Forecast Year [2032] USD 17.25 billion
CAGR (%) 10.77%

A strategic orientation to the multifaceted vaccine delivery device landscape highlighting clinical needs, engineering evolution, supply chain complexity, and digital integration

The vaccine delivery device field sits at the intersection of clinical need, engineering innovation, and complex regulatory oversight. Recent years have seen a shift from purely mechanical disposables toward integrated systems that combine ergonomics, connectivity, cold chain compatibility, and user safety. This evolution is driven by the dual pressures of expanding immunization programs and the increasing complexity of therapeutic biologics that demand precise dosing, cold chain integrity, and adherence monitoring.

Clinical stakeholders and procurement teams are adapting to an environment where device selection is no longer driven solely by unit cost but by total cost of administration, patient adherence, and lifecycle safety. Manufacturers are responding by investing in design for manufacturability, human factors engineering, and regulatory strategy to support quicker clinical adoption. Meanwhile, healthcare providers require devices that address a range of administration routes and site-of-care constraints, from high-throughput hospital vaccination clinics to home-based administration for chronic therapies.

Given the breadth of device types-from auto-injectors and infusion pumps to needle-free injectors and prefilled syringes-stakeholders must evaluate trade-offs across usability, sterility assurance, compatibility with formulation formats, and environmental footprint. These considerations are increasingly evaluated alongside digital features such as dose tracking, connectivity for adherence programs, and interoperability with electronic health records. As the market matures, the ability to align device selection with clinical protocols, supply chain realities, and patient behavior will be a key determinant of successful deployment.

Converging forces of digital connectivity, human-centered safety, modular manufacturing, regulatory clarity, and supply chain resilience transforming vaccine delivery device dynamics

Multiple transformative shifts are reshaping how vaccine delivery devices are designed, manufactured, regulated, and adopted. First, digital integration and the maturation of connected devices are changing expectations for post-administration monitoring, adherence analytics, and remote clinical oversight. This trend extends beyond basic connectivity to include secure data handling, device authentication, and analytics-ready outputs that inform both individual patient care and population-level immunization strategies.

Second, human-centered design and a renewed focus on safety have elevated preferences for devices that reduce needle-stick risk and improve ease-of-use for non-specialist administrators. This has accelerated interest in needle-free technologies, safety-engineered syringes, and auto-injectors that prioritize intuitive operation under stress. Third, manufacturing strategies are shifting toward modular and flexible platforms that can accommodate multiple device formats and formulation types, enabling faster configuration for emergent needs.

Fourth, regulatory environments are converging around clearer expectations for combination products, cybersecurity for connected devices, and real-world evidence to support post-market surveillance. This regulatory clarity is prompting manufacturers to embed compliance considerations earlier in the development process. Fifth, supply chain resilience and nearshoring are gaining prominence, with organizations re-evaluating supplier concentration, component sourcing, and sterilization capacity to reduce geopolitical and logistic risk. Together, these shifts are creating a landscape in which technological capability, regulatory foresight, and supply chain agility determine which products achieve durable clinical uptake.

Assessment of how tariff measures implemented in 2025 have reshaped supply chain sourcing decisions, procurement frameworks, and device development priorities across the ecosystem

The introduction of tariffs in 2025 affecting trade flows into and out of the United States has produced a set of cumulative impacts that ripple across manufacturers, suppliers, and healthcare providers. Tariff measures have increased the relative cost of imported components used in many device categories, creating immediate pressure on procurement strategies and inducing a re-evaluation of the global supplier base. For devices that rely on precision-molded plastic components, electronic sensors, or sterilization services sourced internationally, the tariff burden has accelerated conversations about local manufacturing or dual-sourcing arrangements.

This dynamic has particular implications for disposable-heavy supply chains where recurring purchases amplify the cost impact. Manufacturers and health systems have had to reconcile the trade-off between short-term price increases and the long-term benefits of onshore capacity such as reduced logistics risk and improved supply continuity. For product development, higher component costs have prompted design-for-cost reviews and, in some cases, product simplification to protect margins while preserving safety and regulatory compliance.

Procurement teams are adapting contract structures and hedging strategies to mitigate volatility, while manufacturers are engaging more closely with tier-one suppliers to identify cost-reduction pathways that do not compromise sterility assurance or performance. At the same time, there is evidence of increased collaboration between device makers and formulation partners to optimize device-drug compatibility and reduce total system costs. The cumulative effect of tariffs has therefore been to accelerate existing trends toward supply chain diversification, localized manufacturing, and closer alignment between device design choices and procurement realities.

In-depth segmentation perspective that connects device typologies, administration pathways, end-user environments, and formulation formats to inform strategic positioning

A granular understanding of segmentation is essential for aligning product strategy with clinical and commercial realities. When viewed through the lens of device type, the landscape comprises auto-injectors, infusion pumps, jet injectors, needle-free injectors, pen injectors, prefilled syringes, and safety syringes. Within auto-injectors, there are disposable devices as well as reusable platforms that divide into electronic and mechanical subtypes, each with distinct implications for lifecycle costs, training burden, and data capture. Infusion pumps span elastomeric, syringe-based, and volumetric approaches, with volumetric options further characterized by ambulatory and floor-mounted systems that serve different care settings and administration volumes.

Jet injectors differentiate between multi-use nozzle architectures and single-use nozzle formats, while needle-free injectors split into liquid and powder delivery modalities; liquid systems further segment into electric, gas-based, and spring-based mechanisms that entail varied power and maintenance considerations. Pen injectors offer disposable and reusable choices, and among reusables there is a split between electronic and mechanical innovators that alter dosing precision and integration potential. Prefilled syringes are available in glass or plastic constructions, with plastic variants subdividing into external needle and integrated needle configurations that influence ease-of-use and disposal practices. Safety syringes come in both active and passive safety implementations, each designed to reduce sharps injuries and support compliance with occupational safety requirements.

Administration route is a complementary axis of segmentation, encompassing intradermal, intramuscular, intravenous, mucosal, and subcutaneous approaches. Mucosal delivery further bifurcates into nasal and oral pathways, each presenting unique formulation and device interface challenges. End-user contexts include ambulatory care centers, clinics, home healthcare, and hospitals; within clinics, the needs of primary care and specialty clinics diverge based on throughput, staff expertise, and therapeutic focus. Product form is another critical discriminator, with liquid and lyophilized formulations presenting different handling, reconstitution, and device compatibility requirements. Both liquid and lyophilized families can be packaged in multi-dose or single-dose vials, and those choices influence device selection, waste management, and cold chain logistics. An integrated segmentation strategy that aligns device type, administration route, end-user setting, and product form is therefore essential to matching solution capabilities with clinical workflows and procurement constraints.

Regional contrasts and adoption dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence device selection, manufacturing, and procurement

Regional dynamics continue to shape technology adoption, regulatory pathways, and supplier relationships in distinct ways. In the Americas, procurement models and large immunization programs create demand for devices that balance unit efficiency with safety, and there is growing traction for connected devices that can integrate with immunization registries and electronic medical records. This region also exhibits accelerated conversations about nearshoring and manufacturing scale-up to buffer against global supply interruptions.

Across Europe, Middle East & Africa, regulatory convergence and emphasis on patient safety drive interest in safety-engineered syringes and needle-free alternatives, while divergent procurement capacities produce a spectrum of adoption rates and device preferences. In high-income markets within this region, digital integration and lifecycle service offerings are becoming differentiators, whereas in resource-constrained settings the emphasis remains on simplicity, robustness, and cold chain efficiency.

Asia-Pacific presents a heterogeneous mix of rapid industrial capability, domestic manufacturing ambitions, and varied regulatory regimes. Several markets in this region are scaling local production capacity for both devices and formulation fill-finish, and there is strong interest in cost-effective disposable platforms as well as innovative needle-free technologies that can support mass immunization campaigns. Across all regions, differences in clinical practice, reimbursement models, and supply chain architecture mean that a one-size-fits-all device strategy is unlikely to succeed; instead, regionalized product adaptations and partnerships are needed to achieve both clinical and commercial objectives.

How corporate platform strategies, strategic alliances, regulatory positioning, and service models are redefining competitive advantage among device manufacturers

The competitive and collaborative behavior of key companies is shaping the evolution of vaccine delivery devices in several predictable ways. Leading manufacturers are investing in platform strategies that allow them to extend device functionality across multiple therapeutic areas while amortizing development and regulatory costs. Partnerships between device firms and biologics developers are increasingly common, reflecting the need to validate device-drug compatibility early in development and to design integrated patient support programs.

Supply-side consolidation and strategic alliances are visible where sterilization capacity, component supply, and high-volume assembly create barriers to rapid scaling. At the same time, smaller innovators are driving niche advances in needle-free technologies, micro-dosing, and digital adherence tools that incumbents may choose to acquire or integrate through licensing. Regulatory approvals and clearance pathways remain central competitive battlegrounds, and companies that demonstrate robust human factors testing, cybersecurity assurances, and post-market evidence generation can more readily secure health-system adoption.

Service models-ranging from device-as-a-service to full lifecycle support contracts that include training, maintenance, and data analytics-are emerging as differentiators that influence procurement decisions. Companies that are able to couple product quality with dependable supply and responsive service will command stronger positioning, particularly in markets where operational continuity and clinical outcomes are closely scrutinized.

Practical strategic moves for device manufacturers and health providers to enhance resilience, accelerate adoption, and capture sustained value across care settings

Industry leaders should adopt a multi-pronged strategy that balances short-term resilience with long-term innovation. First, diversify supplier portfolios and invest in dual-sourcing for critical components while evaluating nearshoring opportunities to reduce exposure to tariff volatility and logistic disruption. Second, prioritize modular product platforms that allow rapid reconfiguration between disposable and reusable elements, and design for interoperability with digital health ecosystems to extend clinical value.

Third, embed regulatory strategy and human factors engineering early in the development lifecycle to reduce time-to-adoption risk and to support clear labeling and post-market surveillance plans. Fourth, pursue partnerships with formulation developers to ensure device-drug compatibility is optimized for both liquid and lyophilized presentations, and adapt device interfaces to the practical needs of primary care, specialty clinics, hospitals, ambulatory centers, and home healthcare settings. Fifth, consider services that go beyond the device itself-training, maintenance, data analytics, and lifecycle management-to create differentiated procurement propositions that lower total cost of administration and improve clinical adherence.

Finally, embrace evidence generation that demonstrates real-world performance, safety, and user preference. Operational pilots, pragmatic usability studies, and registry data can accelerate payer and provider acceptance. By aligning product design with procurement realities and clinical workflows, industry leaders can reduce adoption friction and create durable pathways to scale.

Comprehensive mixed-methods research approach combining primary interviews, regulatory and patent review, supply chain mapping, and scenario analysis to validate insights

This research synthesizes diverse data streams to ensure robust, evidence-based conclusions. Primary research included structured interviews with device engineers, clinical leaders across hospital and ambulatory settings, procurement officers, and regulatory experts to capture experiential insights on device performance, usability, and supply constraints. Expert workshops and advisory panels informed interpretations of clinical workflows and the practical trade-offs clinicians face when selecting devices for different administration routes and product forms.

Secondary research encompassed public regulatory filings, guidance documents, patent literature, manufacturer technical specifications, and peer-reviewed clinical studies to validate design claims and safety profiles. Supply chain mapping combined vendor disclosures, logistics data, and trade flow analysis to identify concentration risks and potential resiliency strategies. Where appropriate, human factors and usability testing reports were reviewed to assess user error risks and training needs.

Analytic approaches included cross-validation of qualitative findings with documentary evidence, scenario stress-testing of supply chain responses to tariff and disruption events, and thematic synthesis of technology adoption drivers. Care was taken to triangulate claims from manufacturers with independent clinical and procurement perspectives to deliver balanced, actionable insights. Limitations of the research were mitigated by seeking multiple sources for critical assertions and by documenting areas where data scarcity requires cautious interpretation.

Synthesis of strategic imperatives showing how technology, regulation, segmentation, and supply resilience must converge to enable effective vaccine delivery solutions

The vaccine delivery device landscape is undergoing a period of purposeful transformation driven by technological capability, regulatory evolution, and heightened expectations around safety and supply resilience. Device innovation is increasingly judged by its ability to deliver measurable improvements in clinical workflows, adherence, and total system reliability rather than by discrete product features alone. Supply chain and trade dynamics have accelerated strategic shifts such as diversification of suppliers, modular manufacturing approaches, and a renewed emphasis on localized capacity where it delivers operational advantages.

Segmentation across device types, administration routes, end-user settings, and formulation formats remains essential for matching solution attributes to practical use cases. Regional differences underscore the need for adaptable strategies that consider procurement mechanisms, regulatory regimes, and infrastructure constraints. Companies that marry robust product engineering with thoughtful regulatory planning, service-oriented business models, and targeted evidence generation will be best positioned to secure durable adoption. The path forward requires coordinated action across design, manufacturing, and commercial functions to translate promising technologies into sustainable improvements in vaccine delivery and public health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Delivery Devices Market, by Device Type

  • 8.1. Auto-Injectors
    • 8.1.1. Disposable Auto-Injectors
    • 8.1.2. Electronic Reusable Auto-Injectors
    • 8.1.3. Mechanical Reusable Auto-Injectors
  • 8.2. Infusion Pumps
    • 8.2.1. Elastomeric Pumps
    • 8.2.2. Syringe Pumps
    • 8.2.3. Volumetric Pumps
      • 8.2.3.1. Ambulatory Volumetric Pumps
      • 8.2.3.2. Floor-Mounted Volumetric Pumps
  • 8.3. Jet Injectors
  • 8.4. Needle-Free Injectors
    • 8.4.1. Liquid Injectors
    • 8.4.2. Powder Injectors
  • 8.5. Pen Injectors
    • 8.5.1. Disposable Pen Injectors
    • 8.5.2. Reusable Pen Injectors
      • 8.5.2.1. Electronic Reusable Pen Injectors
      • 8.5.2.2. Mechanical Reusable Pen Injectors
  • 8.6. Prefilled Syringes

9. Vaccine Delivery Devices Market, by Administration Route

  • 9.1. Intradermal Injection
  • 9.2. Intramuscular Injection
  • 9.3. Intravenous Injection
  • 9.4. Mucosal Delivery
    • 9.4.1. Nasal Delivery
    • 9.4.2. Oral Delivery
  • 9.5. Subcutaneous Injection

10. Vaccine Delivery Devices Market, by Product Form

  • 10.1. Liquid Formulations
  • 10.2. Lyophilized Formulations

11. Vaccine Delivery Devices Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
    • 11.2.1. Primary Care Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Home Healthcare
  • 11.4. Hospitals

12. Vaccine Delivery Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vaccine Delivery Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vaccine Delivery Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vaccine Delivery Devices Market

16. China Vaccine Delivery Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3M Company
  • 17.6. AptarGroup, Inc.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Becton, Dickinson and Company
  • 17.9. Catalent, Inc.
  • 17.10. Consort Medical plc
  • 17.11. Elcam Medical
  • 17.12. Gerresheimer AG
  • 17.13. Inovio Pharmaceuticals, Inc.
  • 17.14. Nipro Corporation
  • 17.15. PharmaJet, Inc.
  • 17.16. SCHOTT AG
  • 17.17. Stevanato Group S.p.A.
  • 17.18. Terumo Corporation
  • 17.19. Vaxxas Pty Ltd
  • 17.20. Vetter Pharma International GmbH
  • 17.21. West Pharmaceutical Services, Inc.
  • 17.22. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELASTOMERIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SYRINGE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY VOLUMETRIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY FLOOR-MOUNTED VOLUMETRIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY JET INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY POWDER INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY DISPOSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ELECTRONIC REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MECHANICAL REUSABLE PEN INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRADERMAL INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY NASAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY ORAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LYOPHILIZED FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LYOPHILIZED FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY LYOPHILIZED FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 249. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 288. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. G7 VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 290. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 294. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 295. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY NEEDLE-FREE INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY REUSABLE PEN INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY MUCOSAL DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 300. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 301. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. NATO VACCINE DELIVERY DEVICES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL VACCINE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY AUTO-INJECTORS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES VACCINE DELIVERY DEVICES MARKET SIZE, BY VOLUMETRIC PUMPS, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES VACCINE DELIVE